Workflow
润迈德(02297) - 2024 - 年度业绩
RAINMEDRAINMED(HK:02297)2024-09-10 12:40

Announcement Overview This section provides the purpose and background of the announcement, detailing the use of net proceeds from the global offering Purpose and Background of the Announcement This announcement supplements Runmed Medical Co., Ltd.'s 2023 annual report, detailing the use of approximately HK$78.6 million net proceeds from the global offering as of December 31, 2023 - This announcement is a supplementary disclosure to Runmed Medical Co., Ltd.'s (Stock Code: 2297) 2023 annual report1 - The primary purpose is to provide specific details on the use of approximately HK$78.6 million net proceeds from the global offering as of December 31, 20231 Use of Net Proceeds from Global Offering This section details the allocation and utilization of the HK$78.6 million net proceeds from the global offering across various strategic initiatives Allocation and Utilization of Net Proceeds As of December 31, 2023, the company fully utilized the HK$78.6 million net proceeds from the global offering, with HK$42.3 million used in 2023, primarily for R&D, production, and commercialization of core and pipeline products Allocation and Utilization of Net Proceeds from Global Offering (As of December 31, 2023) | Intended Use of Net Proceeds | Approximate Percentage of Total Net Proceeds | Net Proceeds Allocated (HK$ million) | Balance as of December 31, 2022 (HK$ million) | Net Proceeds Utilized in 2023 (HK$ million) | Balance as of December 31, 2023 (HK$ million) | | :------------------------------------------------------------------------------------------------ | :------------------------------------------- | :----------------------------------- | :-------------------------------------------- | :------------------------------------------ | :-------------------------------------------- | | Ongoing R&D, further clinical studies, registration preparation, production, and commercialization of core products caFFR and caIMR systems | 80.0% | 62.9 | 35.1 | 35.1 | – | | Ongoing R&D, production, and commercialization of other pipeline products | 16.5% | 13.0 | 7.2 | 7.2 | – | | General working capital and general corporate purposes | 3.5% | 2.7 | – | – | – | | Total | 100.0% | 78.6 | 42.3 | 42.3 | | - As of December 31, 2023, the HK$78.6 million net proceeds from the global offering were fully utilized, with HK$42.3 million utilized in 20231 R&D and Commercialization of Core Products The company allocated 80.0% of net proceeds (HK$62.9 million) to R&D, clinical studies, registration, production, and commercialization of caFFR and caIMR systems, fully utilized by December 31, 2023 Fund Utilization for R&D and Commercialization of Core Products | Metric | Amount (HK$ million) | | :-------------------------- | :------------------- | | Allocated Amount | 62.9 | | Amount Utilized in 2023 | 35.1 | | Balance as of December 31, 2023 | – | - 80.0% of the net proceeds (HK$62.9 million) were allocated for ongoing R&D, clinical studies, registration, production, and commercialization of the core caFFR and caIMR systems1 R&D and Commercialization of Other Pipeline Products 16.5% of net proceeds (HK$13.0 million) were allocated for ongoing R&D, production, and commercialization of other pipeline products, fully utilized by December 31, 2023 Fund Utilization for R&D and Commercialization of Other Pipeline Products | Metric | Amount (HK$ million) | | :-------------------------- | :------------------- | | Allocated Amount | 13.0 | | Amount Utilized in 2023 | 7.2 | | Balance as of December 31, 2023 | – | - 16.5% of the net proceeds (HK$13.0 million) were allocated for ongoing R&D, production, and commercialization of other pipeline products1 General Working Capital and Corporate Purposes 3.5% of net proceeds (HK$2.7 million) were allocated for general working capital and corporate purposes, fully utilized by December 31, 2023 Fund Utilization for General Working Capital and Corporate Purposes | Metric | Amount (HK$ million) | | :-------------------------- | :------------------- | | Allocated Amount | 2.7 | | Amount Utilized in 2023 | – | | Balance as of December 31, 2023 | – | - 3.5% of the net proceeds (HK$2.7 million) were allocated for general working capital and corporate purposes1 Other Information This section clarifies the impact of this supplementary announcement on the 2023 annual report and details the current composition of the Board of Directors Impact on 2023 Annual Report The information in this supplementary announcement only complements the 2023 annual report, not affecting the accuracy or validity of other disclosed information, with the report's content remaining unchanged - The supplementary information provided in this announcement does not affect other information contained in the 2023 annual report2 - Except for the disclosures in this announcement, other content of the 2023 annual report remains unchanged2 Composition of the Board of Directors As of the announcement date, Runmed Medical Co., Ltd.'s Board of Directors comprises three executive, three non-executive, and three independent non-executive directors - The Board of Directors consists of Mr. Huo Yunfei, Mr. Lyu Yonghui, and Ms. Gu Yang as Executive Directors2 - The Board of Directors includes Dr. Huo Yunlong, Mr. Wang Lin, and Mr. Heng Lei as Non-executive Directors2 - The Board of Directors comprises Mr. Liao Chuanjiang, Mr. Li Haomin, and Mr. Chen Xuefeng as Independent Non-executive Directors2